RecruitMe Clinical Trial

AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS
A study for patients with locally advanced or metastatic solid tumors using study drug RO6958688
Sponsor:Hoffmann-La Roche Ltd
Enrolling:Male and Female Patients
IRB Number:AAAR1902
Contact: Gulam Manji: 212-305-0592 / gam2140@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find out, as a main objective, at which doses RO6958688 (study drug) can be administered safely to subjects in combination with atezolizumab (study drug), and what the side effects are when both drugs are given together. Additionally, the effects of RO6958688 and atezolizumab in the body, and particularly in the tumor, will be evaluated. The study also aims to find out if RO6958688 in combination with atezolizumab can slow down the growth of tumors or stop the cancer, in subjects with locally advanced and/or metastatic solid tumors. This study is for subjects whose tumors cells express the carcinoembryonic antigen (CEA), which is the target of RO6958688.

This study is closed
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Gulam Manji
Email: gam2140@cumc.columbia.edu
Phone: 212-305-0592